Skip to main content

Study

BPC-157 Infusion Shows No Adverse Effects in Adults Over 50

A small study found that intravenous BPC-157 was safe and well-tolerated in two healthy adults over 50.

Bone Health
Study Credibility: Medium5.8/10Some supporting evidenceStudy has limitationsUse with caution
PublishedNov 2025Last reviewedFeb 2026
Email this

Summary

In plain language

Researchers conducted a small study to test the safety of a peptide called BPC-157 when given through an intravenous infusion. This study involved two participants: a 58-year-old man and a 68-year-old woman, both of whom had received the treatment before. They received BPC-157 in increasing doses over two days. The study found no negative effects on their heart, liver, kidneys, thyroid, or blood sugar levels, and no side effects were reported. This suggests that BPC-157 may be safe for use in healthy adults, though more research is needed. Seniors interested in this treatment should discuss it with their healthcare providers.

Details

Use the full description to understand the study design, methods, and the limits of the findings.

A small-scale pilot study assessing the safety and tolerability of intravenous BPC-157. Results show it is well tolerated in humans under controlled settings, though larger clinical trials are needed.

Research Quality Score

Scored February 1, 2026 using rubric v6_2026-02-01.

Assessment

The study provides preliminary evidence on the safety of BPC-157 but is limited by its small sample size and pilot nature. It lacks the robustness of larger, more comprehensive studies. While it is a credible early investigation, it should be interpreted with caution, especially for senior populations.

Category Breakdown

CategoryScoreRating
Study design5.0/10
Bias control6.0/10
Statistical methods5.0/10
Reporting completeness7.0/10
Conflicts & funding8.0/10
Replication4.0/10
Relevance to chosen population5.0/10
Journal Reliability7.0/10

Additional Notes

Further research with larger sample sizes and specific focus on older adults is needed to strengthen the evidence base.

Take the next step

Build a personalized plan using research-backed studies, conditions, and treatments.